

Singular Health Group Ltd: SHG

ASX Announcement

18th October 2023

Singular Health Receives R&D Tax Incentive Refund

18 October 2023 – Medical technology company Singular Health Group Limited (ASX: SHG, “Singular Health”, or the “Company”) is pleased to announce that it has received an R&D Tax incentive refund of \$823,475 relating to its R&D activities in FY2023.

This refund is the gross R&D refund amount for FY2023, with \$458,984 subsequently repaid to Radium Capital in respect of the R&D funding facility provided in April 2023 (see ASX Announcement: Singular 3DP Operational Update, R&D Funding Facility and Strategic Review, 6th April 2023).

The Company confirms it has now repaid in full the loan from Radium Capital with the balance of funds to go toward general working capital.

Singular Health’s wholly owned subsidiary, Singular 3DP, is also eligible to submit an R&D tax incentive claim for its R&D activities in H2 FY2023 and is expected to lodge a claim of ~\$120,000 in the coming weeks.

Singular Health’s Chief Executive Officer and Managing Director, Denning Chong, said:

“Our ongoing research and development activities throughout the past financial year included activities such as the integration of our 3Dicom MD™ software with Sony Electronic’s Spatial Reality Displays, the further development of our Medical File Transfer Protocol and hybrid on device and cloud infrastructure, and research with new, more cost-effective materials in our 3D printing facility.

“We appreciate the support provided by the Australian government’s R&D tax incentive as we utilise our 100% in-house, West-Australian based talent to develop solutions that are already improving patient outcomes on National and International levels.”

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices. It also provides hardware solutions as an official reseller of the 3D Systems, Kings 3D, and DyeMansion brands in the Australian and New Zealand markets.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>